Detailed information for compound 156471

Basic information

Technical information
  • TDR Targets ID: 156471
  • Name: [3-[2-[4-(1H-benzimidazole-2-carbonyl)piperid in-1-yl]ethyl]-3-(3,4-dimethoxyphenyl)pyrroli din-1-yl]-(3,4,5-trimethoxyphenyl)methanone
  • MW: 656.768 | Formula: C37H44N4O7
  • H donors: 1 H acceptors: 3 LogP: 5.26 Rotable bonds: 13
    Rule of 5 violations (Lipinski): 2
  • SMILES: COc1cc(ccc1OC)C1(CCN2CCC(CC2)C(=O)c2nc3c([nH]2)cccc3)CCN(C1)C(=O)c1cc(OC)c(c(c1)OC)OC
  • InChi: 1S/C37H44N4O7/c1-44-29-11-10-26(22-30(29)45-2)37(15-19-41(23-37)36(43)25-20-31(46-3)34(48-5)32(21-25)47-4)14-18-40-16-12-24(13-17-40)33(42)35-38-27-8-6-7-9-28(27)39-35/h6-11,20-22,24H,12-19,23H2,1-5H3,(H,38,39)
  • InChiKey: XMRHEUULHFVWJE-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • [3-[2-[4-(1H-benzimidazole-2-carbonyl)-1-piperidyl]ethyl]-3-(3,4-dimethoxyphenyl)pyrrolidin-1-yl]-(3,4,5-trimethoxyphenyl)methanone
  • [3-[2-[4-[1H-benzimidazol-2-yl(oxo)methyl]-1-piperidinyl]ethyl]-3-(3,4-dimethoxyphenyl)-1-pyrrolidinyl]-(3,4,5-trimethoxyphenyl)methanone
  • [3-[2-[4-(1H-benzimidazol-2-ylcarbonyl)piperidin-1-yl]ethyl]-3-(3,4-dimethoxyphenyl)pyrrolidin-1-yl]-(3,4,5-trimethoxyphenyl)methanone
  • [3-[2-[4-(1H-benzimidazole-2-carbonyl)piperidino]ethyl]-3-(3,4-dimethoxyphenyl)pyrrolidino]-(3,4,5-trimethoxyphenyl)methanone
  • [3-[2-[4-(1H-benzimidazol-2-yl-oxomethyl)-1-piperidinyl]ethyl]-3-(3,4-dimethoxyphenyl)-1-pyrrolidinyl]-(3,4,5-trimethoxyphenyl)methanone

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens histamine receptor H1 Starlite/ChEMBL No references
Cavia porcellus Neurokinin 1 receptor Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum ko:K04224 tachykinin receptor 3, putative Get druggable targets OG5_137770 All targets in OG5_137770
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma japonicum ko:K04209 neuropeptide Y receptor, invertebrate, putative Neurokinin 1 receptor   407 aa 341 aa 26.1 %
Schistosoma japonicum ko:K04255 opsin 4 (melanopsin), putative Neurokinin 1 receptor   407 aa 339 aa 20.6 %
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Neurokinin 1 receptor   407 aa 373 aa 23.1 %
Echinococcus granulosus thyrotropin releasing hormone receptor Neurokinin 1 receptor   407 aa 341 aa 22.9 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus granulosus transient receptor potential cation channel 0.035 0.0017 0.0017
Onchocerca volvulus 0.035 0 0.5
Loa Loa (eye worm) hypothetical protein 0.035 0.0017 0.0017
Onchocerca volvulus Transient receptor potential cation channel trpm homolog 0.035 0 0.5
Toxoplasma gondii hypothetical protein 0.035 0 0.5
Echinococcus granulosus transient receptor potential cation channel 0.0351 1 1
Echinococcus granulosus transient receptor potential cation channel 0.035 0.0017 0.0017
Echinococcus multilocularis transient receptor potential cation channel 0.0351 1 1
Schistosoma mansoni transient receptor potential channel 0.0351 0.9983 1
Echinococcus granulosus short transient receptor potential channel 6 0.0351 0.9983 0.9983
Schistosoma mansoni transient receptor potential channel 0.035 0.0017 0.0017
Trypanosoma cruzi inositol 1,4,5-trisphosphate receptor, putative 0.035 0 0.5
Echinococcus multilocularis short transient receptor potential channel 6 0.0351 0.9983 0.9983
Leishmania major calcium channel protein, putative,ion transporter, putative 0.035 0 0.5
Toxoplasma gondii transporter, cation channel family protein 0.035 0 0.5
Leishmania major hypothetical protein, conserved 0.035 0 0.5
Echinococcus multilocularis transient receptor potential cation channel 0.0351 1 1
Trypanosoma cruzi Voltage-dependent calcium channel subunit, putative 0.035 0 0.5
Trichomonas vaginalis voltage and ligand gated potassium channel, putative 0.035 0 0.5
Trypanosoma brucei inositol 1,4,5-trisphosphate receptor 0.035 0 0.5
Toxoplasma gondii transporter, cation channel family protein 0.035 0 0.5
Trichomonas vaginalis voltage and ligand gated potassium channel, putative 0.035 0 0.5
Toxoplasma gondii transporter, cation channel family protein 0.035 0 0.5
Leishmania major hypothetical protein, unknown function 0.035 0 0.5
Toxoplasma gondii hypothetical protein 0.035 0 0.5
Onchocerca volvulus Transient receptor potential cation channel trpm homolog 0.035 0 0.5
Loa Loa (eye worm) hypothetical protein 0.035 0.0017 0.0017
Trypanosoma brucei Voltage-dependent calcium channel subunit, putative 0.035 0 0.5
Schistosoma mansoni transient receptor potential channel 0.035 0.0017 0.0017
Loa Loa (eye worm) hypothetical protein 0.0351 1 1
Toxoplasma gondii 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein 0.035 0 0.5
Toxoplasma gondii 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein 0.035 0 0.5
Echinococcus multilocularis transient receptor potential cation channel 0.035 0.0017 0.0017

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 5.71 nM Antagonistic activity against histamine H1 receptor ChEMBL. No reference
IC50 (functional) = 5.71 nM Antagonistic activity against histamine H1 receptor ChEMBL. No reference
IC50 (functional) = 6.98 nM Antagonistic activity against Tachykinin receptor 1 ChEMBL. No reference
IC50 (functional) = 6.98 nM Antagonistic activity against Tachykinin receptor 1 ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.